BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Probiodrug AG, Collaborators Explain Interplay of Key Suspects in Alzheimer's Disease


5/3/2012 12:13:38 PM

HALLE/SAALE, Germany, May 2, 2012 – Probiodrug AG (Probiodrug), a biotech company developing products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer's disease (AD), today announced its scientists and academics collaborators published seminal findings on the role of pyroglu Aß in AD pathology in the May 2, 2012 online edition of the journal Nature. The new findings add to the growing body of evidence that pyroglu Aß plays a crucial role in the initiation of AD. In addition, the research results further elucidate the mechanism by which pyroglu Aß triggers neuronal toxicity.

The data published today suggest that pyroglu Aß co-aggregates with “normal” Aß peptides to form low molecular weight oligomers (LMOs), which are structurally distinct and far more toxic to cultured neurons than oligomers derived from normal Aß. Moreover, the presence of the neuronal protein tau is essential for toxicity mediated by LMOs that contain pyroglu Aß. The results have been substantiated in transgenic mice designed to express increased levels of pyroglu Aß. In these animals, the pyroglu Aß mediated neuronal loss and gliosis was prevented, if tau expression was shut down. The study is supplemented by results published in the Journal of Neurochemistry (online April 2012). Here the Probiodrug researchers reveal, that the aggregation propensity is caused by the hydrophobic nature of pyroglu Aß.

The scientists also were able to demonstrate that the cytotoxicity is propagated by a prion-like templating mechanism of Aß misfolding initiated by pyroglu Aß: even after strong dilution to a solution containing only 0.000625% pyroglu Aß, the mix after 24h developed enough toxicity to kill 50% of neurons treated with it.

“This publication delivers significant evidence to our hypothesis that pyroglu Aß plays a critical role in the initiation of AD,” said Prof. Dr. Hans-Ulrich Demuth, CSO of Probiodrug. “It was also extremely surprising to us, that the pyroglu Aß containing or propagated low-molecular weight oligomers remain stable for days - in contrast to the short-lived oligomers not formed by the pyroglu Aß initiated mechanism. The new data for the first time demonstrate a relationship between pyroglu Aß oligomer formation and tau protein in the development of neuronal toxicity.”

Konrad Glund, CEO of Probiodrug, adds: “It is a great step forward in our understanding of the disease mechanism. In addition, it supports Probiodrug’s therapeutic approach to block Glutaminyl Cyclase, the enzyme responsible for pyroglu Aß formation, with small molecule inhibitors as a treatment for AD. PQ912, the lead candidate, has just completed phase I trials successfully; the company is now preparing first patient studies.”

About Probiodrug AG

Probiodrug is a biopharmaceutical company dedicated to the discovery and development of small molecule drugs against novel molecular targets for the treatment of neuronal- and inflammatory diseases. The Company has a dominant position in the area of glutaminyl cyclase inhibition. Glutaminyl cyclase, a novel enzyme target discovered and patented by Probiodrug, has a crucial role in the pathogenesis of Alzheimer’s disease (AD) as well as various peripheral inflammatory diseases.

Probiodrug is backed by institutions such as BB Biotech, Edmond de Rothschild Investment Partners, Goodvent/IBG, HBM, TVM, Life Sciences Partners, Biogen Idec Ventures, CFH Group and private investors.

Probiodrug's core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes which play a central role in the maturation of hormones. The Company has pioneered the field of dipeptidyl peptidase 4 (DP4)-inhibition for the treatment of type 2 diabetes. Compounds and technology patents of its DP4 program in diabetes were licensed to various pharmaceutical companies. In 2004, all metabolic assets were sold to (OSI) Pharmaceuticals Ltd. The first drug based on Probiodrug`s technologies reached the market in late 2006. Proceeds of the various transactions have been reinvested to fund the novel approach for the treatment of AD and inflammatory diseases. The Company was founded in 1997 by Prof Dr Hans-Ulrich Demuth and Dr Konrad Glund. Probiodrug has raised EUR 71 mio for its QC program. For more information, please visit www.probiodrug.de.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES